Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 12 07 2020
accepted: 03 08 2020
pubmed: 17 8 2020
medline: 6 10 2020
entrez: 16 8 2020
Statut: ppublish

Résumé

Fast and reliable detection of SARS-CoV-2 is crucial for efficient control of the COVID-19 pandemic. Due to the high demand for SARS-CoV-2 testing there is a worldwide shortage of RNA extraction reagents. Therefore, extraction-free RT-qPCR protocols are urgently needed. To establish a rapid RT-qPCR protocol for the detection of SARS-CoV-2 without the need of RNA extraction suitable for all respiratory materials. Different SARS-CoV-2 positive respiratory materials from our routine laboratory were used as crude material after heat inactivation in direct RT-qPCR with the PrimeDirect™ Probe RT-qPCR Mix (TaKaRa). SARS-CoV-2 was detected using novel primers targeted to the E-gene. The protocol for the detection of SARS-CoV-2 in crude material used a prepared frozen-PCR mix with optimized primers and 5 μl of fresh, undiluted and pre-analytically heat inactivated respiratory material. For validation, 91 respiratory samples were analyzed in direct comparison to classical RNA-based RT-qPCR. Overall 81.3 % of the samples were detected in both assays with a strong correlation between both Ct values (r = 0.8492, p < 0.0001). The SARS-CoV-2 detection rate by direct RT-qPCR was 95.8 % for Ct values <35. All negative samples were characterized by low viral loads (Ct >35) and/or long storage times before sample processing. Direct RT-qPCR is a suitable alternative to classical RNA RT-qPCR, provided that only fresh samples (storage <1 week) are used. RNA extraction should be considered if samples have longer storage times or if PCR inhibition is observed. In summary, this protocol is fast, inexpensive and suitable for all respiratory materials.

Sections du résumé

BACKGROUND BACKGROUND
Fast and reliable detection of SARS-CoV-2 is crucial for efficient control of the COVID-19 pandemic. Due to the high demand for SARS-CoV-2 testing there is a worldwide shortage of RNA extraction reagents. Therefore, extraction-free RT-qPCR protocols are urgently needed.
OBJECTIVES OBJECTIVE
To establish a rapid RT-qPCR protocol for the detection of SARS-CoV-2 without the need of RNA extraction suitable for all respiratory materials.
MATERIAL AND METHODS METHODS
Different SARS-CoV-2 positive respiratory materials from our routine laboratory were used as crude material after heat inactivation in direct RT-qPCR with the PrimeDirect™ Probe RT-qPCR Mix (TaKaRa). SARS-CoV-2 was detected using novel primers targeted to the E-gene.
RESULTS RESULTS
The protocol for the detection of SARS-CoV-2 in crude material used a prepared frozen-PCR mix with optimized primers and 5 μl of fresh, undiluted and pre-analytically heat inactivated respiratory material. For validation, 91 respiratory samples were analyzed in direct comparison to classical RNA-based RT-qPCR. Overall 81.3 % of the samples were detected in both assays with a strong correlation between both Ct values (r = 0.8492, p < 0.0001). The SARS-CoV-2 detection rate by direct RT-qPCR was 95.8 % for Ct values <35. All negative samples were characterized by low viral loads (Ct >35) and/or long storage times before sample processing.
CONCLUSION CONCLUSIONS
Direct RT-qPCR is a suitable alternative to classical RNA RT-qPCR, provided that only fresh samples (storage <1 week) are used. RNA extraction should be considered if samples have longer storage times or if PCR inhibition is observed. In summary, this protocol is fast, inexpensive and suitable for all respiratory materials.

Identifiants

pubmed: 32795959
pii: S1386-6532(20)30321-8
doi: 10.1016/j.jcv.2020.104579
pmc: PMC7405857
pii:
doi:

Substances chimiques

DNA Primers 0
RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104579

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Références

Int J Infect Dis. 2020 Aug;97:66-68
pubmed: 32492531
PLoS One. 2020 Jul 24;15(7):e0236564
pubmed: 32706827
Nat Commun. 2020 Sep 23;11(1):4812
pubmed: 32968075
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
PLoS Biol. 2020 Oct 2;18(10):e3000896
pubmed: 33006983
Lancet Infect Dis. 2020 Nov;20(11):1231-1232
pubmed: 32530425
PLoS One. 2020 Nov 2;15(11):e0238612
pubmed: 33137122
Euro Surveill. 2020 Apr;25(14):
pubmed: 32290905
Clin Microbiol Infect. 2020 Jun;26(6):773-779
pubmed: 32276116
Clin Infect Dis. 2020 May 22;:
pubmed: 32442256
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Genes (Basel). 2020 Jun 18;11(6):
pubmed: 32570810
J Clin Virol. 2020 Jul;128:104423
pubmed: 32416598

Auteurs

Nadine Lübke (N)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany. Electronic address: nadine.luebke@med.uni-duesseldorf.de.

Tina Senff (T)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.

Sara Scherger (S)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.

Sandra Hauka (S)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.

Marcel Andrée (M)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.

Ortwin Adams (O)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.

Jörg Timm (J)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.

Andreas Walker (A)

Institute of Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH